INSM Form 4: Michael A. Smith Exercises 12,780 Options and Sells Shares Under 10b5-1
Rhea-AI Filing Summary
Insmed, Inc. (INSM) Chief Legal Officer Michael A. Smith reported transactions on 09/02/2025. Mr. Smith exercised stock options to acquire 12,780 shares at an exercise price of $30.46 and immediately sold multiple blocks of common stock under a Rule 10b5-1 trading plan. The sales totaled 24,252 shares at weighted average prices ranging from $140.58 to $146.04 per share, reducing his reported beneficial ownership from 79,174 shares to 54,902 shares. All exercised options are currently exercisable and the transactions were effected pursuant to a 10b5-1 plan adopted February 27, 2025.
Positive
- Transactions executed under a documented 10b5-1 plan, indicating pre-planned trading and compliance with insider trading rules.
- Full disclosure of weighted average sale prices with commitment to provide per-price breakdowns on request, supporting transparency.
Negative
- Reported beneficial ownership decreased materially from 79,174 shares to 54,902 shares after the transactions.
- Insider sold 24,252 shares in multiple tranches on the same date, representing significant insider monetization.
Insights
TL;DR: Insider exercised options and sold shares under a pre-established 10b5-1 plan; notable execution size but routine in structure.
The exercise of 12,780 options at $30.46 followed by sales of 24,252 shares generated cash proceeds at prices between $140.58 and $146.04, materially reducing the reporting person's holdings by approximately 30% of pre-transaction shares. Because the sales were executed under a documented 10b5-1 plan, this suggests pre-planned liquidity rather than ad hoc disposition. The transactions do not, by themselves, indicate operational issues at the company but do increase public float and reflect insider monetization of vested equity.
TL;DR: Transactions comply with Rule 10b5-1; transparency is good, but reduced insider stake is noteworthy.
The filing clearly discloses adoption date of the 10b5-1 plan and weighted average sale prices for each sale tranche with undertakings to provide per-price breakdowns on request, which aligns with strong disclosure practices. The reduction in beneficial ownership from 79,174 to 54,902 shares is substantial for a single officer and may modestly alter perceptions of insider alignment with shareholders, although no governance rule violations are indicated.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (right to buy) | 12,780 | $0.00 | -- |
| Exercise | Common Stock | 12,780 | $30.46 | $389K |
| Sale | Common Stock | 1,354 | $141.16 | $191K |
| Sale | Common Stock | 1,100 | $142.06 | $156K |
| Sale | Common Stock | 7,391 | $143.16 | $1.06M |
| Sale | Common Stock | 8,300 | $144.16 | $1.20M |
| Sale | Common Stock | 4,944 | $145.18 | $718K |
| Sale | Common Stock | 1,183 | $145.89 | $173K |
Footnotes (1)
- This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on February 27, 2025, in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. This is the weighted average sales price representing 1,354 shares sold at prices ranging from $140.58 to $141.50 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. This is the weighted average sales price representing 1,100 shares sold at prices ranging from $141.58 to $142.55 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. This is the weighted average sales price representing 7,391 shares sold at prices ranging from $142.70 to $143.63 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. This is the weighted average sales price representing 8,300 shares sold at prices ranging from $143.72 to $144.71 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. This is the weighted average sales price representing 4,944 shares sold at prices ranging from $144.72 to $145.57 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. This is the weighted average sales price representing 1,183 shares sold at prices ranging from $145.75 to $146.04 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. The options became exercisable based on the following vesting schedule: 25% vested on the first anniversary of the grant date and an additional 12.5% vested on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant. All options are currently exercisable.
